The lazy summer vacation season is upon us, but biotech isn’t taking any time off.
Catch up on your headlines from the past couple weeks here.
Juno Therapeutics and the Quest to Engineer T-cells to Fight Cancer
Immunotherapy, a catch-all term for stimulating the immune system to fight cancer cells, is giving rise to an exciting new movement in cancer treatment. If you’ve never heard of chimeric antigen receptor-modified T-cells (CAR-T) cells, or only have a faint sense of what Seattle-based Juno Therapeutics is all about and why it’s worth more than $4.5 billion, then do yourself a favor and read this excellent explanatory feature by Antonio Regalado of Technology Review.
Hey, check out all the research scientist jobs. Post your resume today!
